| Author | Date | Design | Rx | N | Duration, yrs | BMD spine PRE | BMD hip PRE | Spine loss | Hip loss | Fxs | AVN | PTH | Comments |
| Ramsey-Goldman | 99 | retro | . | 432 | 2 since tx | . | . | . | . | 0.076 | . | . | symptomatic fxs; 14 of 33 were foot fxs |
| Cueto-Manzano | 99 | xs, bxs | . | 45 | 10 yrs post tx | . | . | not significant, z = -.8 to +.3 | not significant, z = -.5 | 2 of 45 | 1 of 45 | still high, mean 65-85, 14% OFib on bx | reported BMD based on histologic type; z-score spine +.8 in Nl, -.3 in mixed, or hyperpara, -.4 in adynamic; markers showed high NTX |
| Dissanayake | 98 | review | . | . | . | . | . | . | . | . | . | . | . |
| Iskilar | 98 | pros | . | 26 | 0.5 | . | . | -0.065 | . | . | . | BMD loss similar in high vs low PTH | . |
| Lippuner | 98 | RCT dbbl | deflazacort vs pred | 24 | 3.25 | no z scores | . | Pred - 8%, defl - 1.4% | yes ~-4% both gps | . | . | high at tx, then decreased both gps 106-62 | . |
| Grotz | 98 | RCT | clodronate, calcitonin | 46 | 1 yr | . | . | +4.6% clod, +3.2% calcit, +1.8% cont | -1.1 clod, +2.5 calcit,..-0.8 cont | . | . | inc 116% with Rx | took drugs only 14 days q 3 mo; pts 4-5 yrs post tx; no sign diff between groups |
| Massari | 97 | review | . | . | . | . | . | . | . | . | . | . | . |
| Sevaux | 97a | pros | . | 46 | 0.5 | z=-.39 | . | -0.061 | . | . | . | 20 to 8 | pts had low 1,25 vit D |
| Dumoulin | 97 | xs | . | . | . | . | . | . | . | . | . | . | urine oxalate up but no increase in stone-forming potential |
| Aroldi | 97 | RCT | CsA alone vs with steroids | 53 | 1.5 | z=-.99 | . | CsA alone +5.3%, with steroids or aza. -7.8% | . | . | . | . | 5/20 pts on CsA alone had to drop due to rejection; many others also dropped from study; 4 had "symptomatic bone disease" but the rest had no fx |
| Pichette | 96 | obs, XS&long | . | 70 | 2 | . | . | 2 yrs post tx spine z-1.1, after that ongoing loss of1.7%/yr | hip z-.53 2yrs post tx | 4 vert | . | . | . |
| Vekasquex | 96 | xs, bx | . | 16 | . | . | . | z post tx -1.79 | z post tx -1.88 | . | . | high | 3.5 yrs post tx; many bxs had "low" BFR |
| Moore | 96 | compare | ketoconazole to not | 25 | 0.5 | . | . | greater in those on keto. | . | . | . | . | . |
| Hung | 96 | pros | . | 64 | 3 | nd | . | z =0 in men, -.8 to -1.2 in women at 3 yrs post tx | z=-.3 to -.1 in men, .01 ot -.50 in women | . | . | decreased, still mean 50-75 | separated young vs old men and women..Estrogen levels did not change post tx in premenopausal women, values 153 (nl 10-500) ?when in cycle |
| Giannini | 96a | xs | . | . | . | . | . | low - gave T scores only! | . | . | . | high in 44% of pts | . |
| Setterberg | 96 | xs | 41, half with hypercalcemia | . | . | . | . | worse with hypercalcemia | . | . | . | not mentioned in ab | . |
| McIntyre | 95 | RCT | CsA with or without pred | 22 | 5 | . | . | . | . | . | . | . | arm lost 25% with pred, 5% without |
| Briner | 95 | pros,bxs | . | 34 | 2 | . | . | . | . | 0/34 symptomatic | . | decreased but not to normal; those with nl PTH at tx inc to above nl | BV not changed, still abnormalities seen on bxs; ocalcin dec, 125D inc; stainable Al dec, stil present |
| Grotz | 95 | xs | . | 190 | . | . | . | apparently no sign loss after 2nd year beyond normal loss | . | . | . | . | . |
| Grotz | 95 | obs, some pros | . | 115 | 1 | . | . | -7% year one p tx, -1% year two, then stable, resulting in z-1.0 | . | . | . | correlated with loss rate | range 0 - 20 yrs post tx |
| Wolpaw | 94 | xs | . | 65 | . | . | . | . | . | . | . | . | ab gives % below Fx thresh |
| Grotz | 94 | xs | . | 100 | . | . | . | . | . | long bones fx in 11% of pts | . | . | mean 5 yrs p tx; fx not predicted by BMD |
| Horber | 94 | pros | . | 34 | 0.5 | z=-.42males, -1.37 females | z -0.06 males, -1.45 females | -0.067 | males -3.7%, females -1.1% | . | . | decreased by 30% | no diabetics |
| Bagni | 94 | xs | . | 44 | . | . | . | z<2 in 18 of 44; show graph but no average z xcore reported | . | 1 vert fx, 2 clin fxs | 7 of 44 | neg correlation to BMD r=.3 | BMD Z inversely corr with time since tx r = .4; free test low in 12/26 men |
| Kalef | 94 | long | . | 20 | 3 | . | . | 52% below nl by QCT, but no change over 3 yrs | . | . | . | . | arm 6.6% below nl |
| Almond | 94 | pros | . | 34 | 1 | z=0 | z=0 | females -4.4% at 12 mo, males ~-2% (NS) | males -5% at 6mo, -2% at 12 mo; females ~-1% (NS) | . | . | . | . |
| Kwan | 92 | pros | . | 26 | 0.5 | not sign. low | not sign. low | -0.028 | -0.042 | . | . | . | same pts as Almond |
| Julian | 91 | pros, bxs | . | 20 | 1.5 | z=-1.2 | . | 0.088 | . | . | . | dec to normal, not corr to bone loss | . |
| Alsina | 89 | pros | . | 42 | 1.5 | . | . | . | . | . | . | dec from 82 to 66% of pts above nl | bone scans got better if PTH normalized, otherwise not |
| Seeman | 89 | long | . | 30 | 1 | . | . | ongoing -5% | men lost fem shaft, women neck | . | . | . | results not significant, conclude BMD nl in renal failure |
| Aubia | 88 | pros, bxs | . | 19 | 1 | . | . | . | . | . | . | . | those on cyclosporin had higher osteoid& resorbing surfaces than azathioprine; both lower than pre-tx |
| Felsenfeld | 86 | xs, bxs | . | 10 | . | . | . | . | . | . | . | . | pts 8 yrs post tx with hypophos had normal bxs except low bone volume |
| Main | 86 | bxs | . | . | . | . | . | . | . | . | . | . | . |
| Eastell | 85 | pros | . | 12 | 1.5 | . | . | . | . | . | . | . | TBC -0.9%/yr except 2 pts who had PTX and had increase |
| Cundy | 81 | obs | . | 18 | 0.1 | . | . | . | . | . | . | . | compared those who got vit D before tx, described cases of hypercalcemia in first month |
| Nielsen | 79 | xs | . | 195 | ? | . | . | . | . | 0.09 | . | . | fxs in 18 of 195 pts mean of 22 mo post tx but f/u time varied..Sites: spine, ribs, pelvic account for 85% of fxs |
| Nixon | 79 | obs | . | 181 | up to 4 | . | . | . | . | 1 | 14 (7.5%) | . | . |
| Huffer | 75 | bxs | . | 35 | . | . | . | . | . | . | . | . | bxs from autopsies of pts who had renal tx, showed high resorption |